A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants

NCT ID: NCT02188251

Last Updated: 2015-08-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2015-04-30

Brief Summary

The purpose of this study is to determine the effects of Activamp, a product containing gynostemma pentaphyllum extract, on body weight, fat loss and metabolic markers in healthy overweight adults.

Conditions

Body Weight

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: TRIPLE

Study Groups

Activamp

Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks

Group Type: EXPERIMENTAL

Activamp

Intervention Type: DIETARY_SUPPLEMENT

Placebo

1 capsule taken twice daily for 12 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Interventions

Activamp

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Healthy male or female 21-55 years of age
• BMI of 25.0 kg/m2 to 29.9 kg/m2 (± 1.0kg/m2)
• Must have negative urine pregnancy test at screening
• Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
• Subject agrees to maintain their normal level of physical activity throughout the study
• Weight has been stable for the last 3 months
• Subject agrees to comply with study procedures
• Healthy as determined by laboratory results, medical history and physical exam
• Subject agrees not to participate in structured activity including resistance training and aerobic exercise more than 3 times per week
• Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria

• Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
• Subject who have experienced a greater than 10% variation in body weight in the past 3 months
• History of, or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems
• History of surgery for weight loss (including gastric bypass or lapband)
• History of conditions that could interfere with the test product or impede its absorption such as gastrointestinal disease (Crohn's disease) or experienced surgery (caecum or enterocele surgery)
• Subjects diagnosed with Type II Diabetes
• Subjects with active cancer (excluding basal cell carcinoma)
• Subjects with active eating disorders
• Subjects who have undergone anti-psychotic drug therapy within the past 2 months
• Use of prescription or over the counter medications known to affect weight within 3 weeks of randomization or during the study
• Use of any supplements, programs, or meal replacement products, other than those provided, intended to alter body weight within two weeks of screening or during the course of the study
• Use of illicit drugs or history of drug or alcohol abuse within the past 6 months
• Currently having more than 2 standard alcoholic drinks per day
• Participation in a clinical research trial within 30 days prior to randomization
• Allergy or sensitivity to test article ingredients
• Individuals who are cognitively impaired and/or who are unable to give informed consent
• Abnormal lab test results or any other medical or psychological condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Gencor Pacific Limited

UNKNOWN

Sponsor Role: collaborator

KGK Science Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dale Wilson, MD

Role: PRINCIPAL_INVESTIGATOR

KGK Science Inc.

Locations

KGK Synergize Inc.

London, Ontario, Canada

Countries

Canada

Other Identifiers

14AWHG

Identifier Type: -

Identifier Source: org_study_id